KROS
Keros TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
KROS vs peer average
90/100
KROS vs. peer average (A vs. C)
Grade spread
A 1 · B 2 · C 2 · D 1 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
DTIL is the first available peer comparator.
Direct indication comparator: Precision BioSciences is advancing PBGENE-DMD in a Phase 1/2 Duchenne study, with initial data expected by year-end 2026. Its gene-editing modality and different stage make it an operating comparator, not a valuation benchmark. [Precision BioSciences IR](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-receives-us-fda-clearance-investigational/)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
KROS
Keros Therapeutics
DTIL
Precision BioSciences
Grade
A
B
Momentum
27
49
Value
61
41
Sentiment
78
73
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs DTIL
KROS / DTIL
Grade Position
Above peers
KROS vs. peer average (A vs. C)
90/100
Momentum
27
DTILValue
61
KROSSentiment
78
KROSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs KROS
DTIL is the first peer returned for this comparison set.